Transurethral microwave thermotherapy

UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH

Retrieved on:

Monday, March 13, 2023

WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world studies of the Prostatic Urethral Lift (PUL) procedure with the UroLift® System, for treating men with benign prostatic hyperplasia (BPH). Results underscore the benefits of early intervention with respect to durability, symptom improvement and sexual function that urologists around the world have come to expect from the UroLift® System, which is the leading minimally invasive, outpatient treatment in the United States for enlarged prostate.1 The research was presented at the 38th Annual European Association of Urology (EAU) Congress taking place in Milan from March 10-13, 2023.

Key Points:

“These important new analyses show that, whether compared to other interventions or medication, the UroLift® System offers unique benefits that make it the treatment of choice for many men searching for long-term relief of burdensome BPH symptoms,” said Jacqueline Welch, Vice President, Global Clinical and Scientific Operations, Teleflex.
Following are key findings from the studies:
PUL with the UroLift® System was durable in most subjects at one and five years.
Additionally, only these TURP subjects experienced high-severity adverse events.4
Outcomes from the largest healthcare utilization study for BPH therapies, including medication5
Procedure complication rates were similar between TURP, Photoselective Vaporization of the Prostate (PVP) and Aquablation®, and lowest for PUL with the UroLift® System.
“The results from these studies emphasize the value of the UroLift® System in successfully treating BPH symptoms, enabling rapid recovery, preserving sexual function, and improving patients’ overall quality of life.”2-5

Olympus Exercises Option to Buy Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth

Retrieved on:

Friday, February 26, 2021

Hospitals, Health, Other Health, Medical devices, Clinical medicine, Medicine, Medical specialties, Transurethral resection of the prostate, Benign prostatic hyperplasia, BPH, Urology, Minimally-invasive surgery, Surgery for benign prostatic hyperplasia, Transurethral microwave thermotherapy, Medi-Tate, Olympus’ Therapeutic Solutions business

Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (BPH).

Key Points:

Medi-Tate is a medical device manufacturer engaged in the research and development, production, and sale of devices for the minimally invasive treatment of benign prostatic hyperplasia (BPH).
The company has identified and focused on gastroenterological endotherapy devices, urological devices and respiratory endotherapy devices as three priority therapeutic areas within TSD.
Olympus develops, manufactures and markets BPH treatment devices for TURP procedures such as resectoscopes and a wide variety of electrodes.
Medi-Tate is an Israeli medical device company dedicated to improving mens healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH).

Benign Prostatic Hyperplasia Treatment Market worth $14.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Thursday, February 11, 2021

Clinical medicine, Medicine, Medical specialties, Andrology, Benign prostatic hyperplasia, Men's Health, BPH, Transurethral microwave thermotherapy, Prostatic stent

Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.

Key Points:

Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.
Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment.
Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.
North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.

Benign Prostatic Hyperplasia Treatment Market worth $14.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on:

Thursday, February 11, 2021

Clinical medicine, Medicine, Medical specialties, Andrology, Benign prostatic hyperplasia, Men's Health, BPH, Transurethral microwave thermotherapy, Prostatic stent

Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.

Key Points:

Drug treatment is expected to hold the largest share of the benign prostatic hyperplasia treatment market, by type in 2021.
Based on the type, the BPH treatment market is segmented into drug treatment and surgical treatment.
Home healthcare is expected to hold the largest share of the benign prostatic hyperplasia treatment market, in 2021.
North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.

Global Benign Prostatic Hyperplasia (BPH) Devices Markets 2020-2025 - Teleflex, KARL STORZ, Lumenis, Urologix, and Boston Scientific are the Key Players

Retrieved on:

Wednesday, January 6, 2021

Medicine, Clinical medicine, Medical specialties, Andrology, Benign prostatic hyperplasia, Men's Health, Hyperplasia, BPH, Benignity, Transurethral microwave thermotherapy

The global benign prostatic hyperplasia devices market is expected to grow at a CAGR of over 22% during the period 2019-2025.

Key Points:

The global benign prostatic hyperplasia devices market is expected to grow at a CAGR of over 22% during the period 2019-2025.
The global benign prostatic hyperplasia (BPH) devices market is expected to observe an absolute growth of over 242% during the forecast period.
In 2019, the hospital end-user was the largest segment in the global benign prostatic hyperplasia devices market.
Teleflex, KARL STORZ, Lumenis, Urologix, and Boston Scientific are the key players in the benign prostatic hyperplasia devices market.

Global Benign Prostatic Hyperplasia (BPH) Devices Market Outlook and Forecast 2020-2025 with In-depth Analysis and Data-driven Insights on the Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on:

Tuesday, January 5, 2021

Medical devices, Health, Medicine, Medical specialties, Clinical medicine, Andrology, Benign prostatic hyperplasia, Men's Health, Hyperplasia, BPH, Benignity, Transurethral microwave thermotherapy

The "Benign Prostatic Hyperplasia (BPH) Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "Benign Prostatic Hyperplasia (BPH) Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global benign prostatic hyperplasia devices market is expected to grow at a CAGR of over 22% during the period 2019-2025.
The global benign prostatic hyperplasia (BPH) devices market is expected to observe an absolute growth of over 242% during the forecast period.
Teleflex, KARL STORZ, Lumenis, Urologix, and Boston Scientific are the key players in the benign prostatic hyperplasia devices market.

Benign Prostatic Hyperplasia (BPH) Devices Market Size to Reach Revenues of around USD 800 Million by 2020 - Arizton

Retrieved on:

Monday, December 14, 2020

Clinical medicine, Medicine, Medical specialties, Andrology, Benign prostatic hyperplasia, Men's Health, BPH, Hyperplasia, Minimally-invasive surgery, Transurethral microwave thermotherapy, Prostate steam treatment

CHICAGO, Dec. 14, 2020 /PRNewswire/ -- The global benign prostatic hyperplasia (BPH) devices market is expected to grow at a CAGR of over 22% during the period 20192025.

Key Points:

CHICAGO, Dec. 14, 2020 /PRNewswire/ -- The global benign prostatic hyperplasia (BPH) devices market is expected to grow at a CAGR of over 22% during the period 20192025.
North America and Europe are expected to grow faster than the global market CAGR, due to high penetration minimally invasive surgical procedures for treating BPH.
In 2019, the hospital end-user was the largest segment in the global benign prostatic hyperplasia devices market.
The volume of outpatient surgeries has increased dramatically over the past three decades due to advances in medical technology and payment incentives.

Benign Prostatic Hyperplasia (BPH) Devices Market Size to Reach Revenues of around USD 800 Million by 2020 - Arizton

Retrieved on:

Monday, December 14, 2020

CHICAGO, Dec. 14, 2020 /PRNewswire/ -- The global benign prostatic hyperplasia (BPH) devices market is expected to grow at a CAGR of over 22% during the period 20192025.

Key Points:

CHICAGO, Dec. 14, 2020 /PRNewswire/ -- The global benign prostatic hyperplasia (BPH) devices market is expected to grow at a CAGR of over 22% during the period 20192025.
North America and Europe are expected to grow faster than the global market CAGR, due to high penetration minimally invasive surgical procedures for treating BPH.
In 2019, the hospital end-user was the largest segment in the global benign prostatic hyperplasia devices market.
The volume of outpatient surgeries has increased dramatically over the past three decades due to advances in medical technology and payment incentives.

NeoTract Designates Dr. Richard Bevan-Thomas as UroLift® Center of Excellence

Retrieved on:

Tuesday, September 8, 2020

Medical specialties, Anatomy, Clinical medicine, RTT, Exocrine system, Glands, Mammal male reproductive system, Prostate, Sexual anatomy, Urology, Teleflex, Transurethral microwave thermotherapy

The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

Key Points:

The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.
The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.
"This designation recognizes Dr. Richard Bevan-Thomas as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH," said Dave Amerson, president of the Teleflex Interventional Urology business unit.
Teleflex is the home of Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, UroLift and Weck trusted brands united by a common sense of purpose

NeoTract Designates Dr. Shawn Todd as UroLift® Center of Excellence

Retrieved on:

Thursday, August 27, 2020

Medical specialties, Clinical medicine, Medicine, Andrology, Benign prostatic hyperplasia, Men's Health, RTT, Urology, BPH, Transurethral microwave thermotherapy

PLEASANTON, Calif., Aug. 27, 2020 /PRNewswire-PRWeb/ --NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Shawn Todd, D.O., Texas Urological Clinic in Lufkin, TX, has been designated as a UroLift Center of Excellence.

Key Points:

PLEASANTON, Calif., Aug. 27, 2020 /PRNewswire-PRWeb/ --NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Shawn Todd, D.O., Texas Urological Clinic in Lufkin, TX, has been designated as a UroLift Center of Excellence.
The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.
"Dr. Shawn Todd has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment," said Dave Amerson, president of the Teleflex Interventional Urology business unit.
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).